Medaffcon’s Post

View organization page for Medaffcon, graphic

3,029 followers

🔦 Medaffcon is Preparing to Conduct RWE Studies in #Neurology and #Psychiatry 💡 In the coming years, breakthroughs in neurological and psychiatric drug research are expected to change treatment practices and significantly improve patients’ quality of life. Medaffcon is contributing to this development by conducting, for example, #RWE studies (Real World Evidence). 🧠 In neurology and psychiatry, new drugs have not been developed as frequently as in fields like cancer treatment. “The risks involved in investing in drug development for neurological and psychiatric diseases are high, as these are difficult-to-measure conditions and trial have had high failure rates. In cancer there are many existing biomarkers and faster trials,” says Medaffcon’s Scientific Advisor, PhD Riikka Mattila.  Mattila has worked, e.g., at the #Neuroscience Center of the University of Helsinki, researching Alzheimer’s disease.  ➡ Read more about the article ➡ https://lnkd.in/dxTPM7NJ #pharmaceutical #scandinavia

  • In the coming years, breakthroughs in neurological and psychiatric drug research are expected to change treatment practices and significantly improve patients’ quality of life. Medaffcon is contributing to this development by conducting, for example, RWE studies (Real World Evidence). 

In neurology and psychiatry, new drugs have not been developed as frequently as in fields like cancer treatment. 

“The risks involved in investing in drug development for neurological and psychiatric diseases are high, as these are difficult-to-measure conditions and trial have had high failure rates. In cancer there are many existing biomarkers and faster trials,” says Medaffcon’s Scientific Advisor, PhD Riikka Mattila. 

Mattila has worked, e.g., at the Neuroscience Center of the University of Helsinki, researching Alzheimer’s disease.
Riikka Mattila

Scientific Advisor, RWE expert

2mo

As more innovative treatments for neurological and psychiatric conditions reach the market, conducting Real World Evidence (RWE) studies on these indications becomes increasingly important. These studies provide invaluable insights into the epidemiology of these illnesses, helping to identify who would be eligible for new treatments and offering a comprehensive view of the current landscape. Additionally, RWE studies reveal how new medications perform in everyday clinical settings, beyond the controlled environment of clinical trials.

To view or add a comment, sign in

Explore topics